Glaukos pays iVeena $10M for eye drop vision loss candidate

Glaukos has struck a deal to license iVeena Delivery Systems’ IVMED-80, paying $10 million upfront for the global rights to the disease-modifying topical eye drop candidate that completed a phase 1/2a trial last year.